** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 8.3% to $3.39 premarket
** Company's experimental immunotherapy to treat early Parkinson's disease was well tolerated with no clinically relevant safety issues, it says citing interim data from a mid-stage study
** Parkinson's disease is a progressive movement disorder of the nervous system, which causes nerve cells in parts of the brain to weaken, become damaged and die
** The therapy, ACI-7104.056, induced high immune response on average 16-fold higher than placebo after 3 immunizations -ACIU
** Company plans to share further data from the study in H1 2025
** Data includes analyses from over 30 patients randomized to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU
** Up to last close, stock down ~37% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。